Retrophin’s Neil McFarlane Named Adamas CEO, Succeeding Gregory Went

Adamas Pharmaceuticals (NASDAQ: [[ticker:ADMS]]) appointed Neil McFarlane to serve as its new CEO. He is also joining the Emeryville, CA, company’s board of directors. McFarlane succeeds Gregory Went, chairman and CEO of Adamas since its inception. Went is stepping down from the board but he will continue to advise the company.

McFarlane was most recently chief operating officer of Retrophin (NASDAQ: [[ticker:RTRX]]). His experience also includes positions at UCB, Genzyme, and Sangstat Medical Corporation. Adamas won FDA approval in 2017 for amantadine (Gocovri), a drug developed to treat involuntary movements associated with Parkinson’s disease. That drug is also in Phase 3 testing as a treatment for walking impairment in multiple sclerosis patients.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan